烟酰胺核糖治疗早期帕金森病的随机临床试验
这项在挪威11个中心开展的随机双盲安慰剂对照3期试验,纳入410例早期帕金森病患者,评估口服烟酰胺核糖500 mg每日两次共52周的疗效。
要点
- 烟酰胺核糖500 mg每日两次治疗52周未改善早期帕金森病临床结局。
- 主要终点MDS-UPDRS总分变化 favoring 安慰剂,差异2.72分(95%CI 0.47-4.98)。
- 非运动症状量表(NMSS)评分在烟酰胺核糖组恶化更明显(差异4.22分)。
核心结论
- 在早期帕金森病患者中,烟酰胺核糖治疗52周未改善临床结局,且临床结局较安慰剂更差。
- 这些发现不支持烟酰胺核糖作为帕金森病的疾病修饰治疗。
研究设计与样本
- 随机、双盲、安慰剂对照的3期临床试验,在挪威11个中心开展。
- 纳入年龄≥35岁、确诊帕金森病≤2年、Hoehn和Yahr分期<3、多巴胺转运体显像异常且多巴胺能治疗稳定的患者。
- 筛查537例,随机410例(烟酰胺核糖500 mg每日两次 n=206;安慰剂 n=204),393例纳入主要分析。
- 干预52周,主要终点为基线至第52周MDS-UPDRS总分(第I-III部分)变化。
主要发现
- 安全性人群中,严重不良事件在烟酰胺核糖组发生17/205例(8.3%),安慰剂组29/205例(14.1%)。
关键数值与推荐
- 主要终点MDS-UPDRS总分范围0-236分,改善和恶化的临床重要差异分别为6.7分和5.2分。
- NMSS评分范围0-360分,分数越高表示非运动症状负担越重。
临床怎么用
- 基于本试验结果,不应将烟酰胺核糖用于早期帕金森病的疾病修饰治疗。
- 临床决策时应考虑烟酰胺核糖可能加重非运动症状负担并导致临床结局恶化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Nicotinamide riboside, a nicotinamide adenine dinucleotide precursor, has been proposed as a potential disease-modifying therapy for Parkinson disease based on preclinical and early studies. Whether prolonged oral nicotinamide riboside improves clinical outcomes in Parkinson disease is unknown. OBJECTIVE: To determine whether nicotinamide riboside improves clinical outcomes in Parkinson disease compared with placebo. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 11 centers in Norway. Eligible participants were patients aged 35 years or older with Parkinson disease diagnosed within 2 years before enrollment, Hoehn and Yahr disease stage less than 3, abnormal dopamine transporter scintigraphy findings confirming dopaminergic nigrostriatal denervation, and stable dopaminergic treatment before enrollment. Of 537 screened individuals, 410 were randomized from May 6, 2020, to June 20, 2024, and 393 were included in the primary analysis. Final follow-up was completed on June 19, 2025. INTERVENTIONS: Patients were randomized to receive oral nicotinamide riboside, 500 mg twice daily (n = 206), or matching placebo (n = 204) for 52 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was change from baseline to week 52 in the Movement Disorder Society Unified Parkinson Disease Rating Scale total score (MDS-UPDRS parts I-III; range, 0-236, with higher scores indicating more severe disease; clinically important differences for improvement and worsening, 6.7 and 5.2 points, respectively), analyzed using a mixed model for repeated measures. The 5 key secondary outcomes were the individual parts I, II, and III of the MDS-UPDRS; dopamine transporter single-photon emission computed tomography brain imaging findings; and the Non-Motor Symptoms Scale score (NMSS; range, 0-360, with higher scores indicating greater nonmotor symptom burden). RESULTS: Among the 393 participants in the primary analysis, the mean age was 65.6 (SD, 9.4) years and 133 (34%) were female. At week 52, the total MDS-UPDRS score increased by 2.45 (95% CI, 0.80-4.10) points with nicotinamide riboside and decreased by 0.27 (95% CI, -1.95 to 1.40) points with placebo, yielding an adjusted mean difference of 2.72 points (95% CI, 0.47-4.98 points; P = .02), favoring placebo. Of the 5 prespecified key secondary outcomes, 4 showed no significant difference, but nonmotor symptom burden worsened more with nicotinamide riboside (NMSS score adjusted mean difference, 4.22 [95% CI, 1.07-7.37] points; P = .009). Serious adverse events occurred in 17 (8.3%) of 205 participants receiving nicotinamide riboside and 29 (14.1%) of 205 receiving placebo in the safety population. CONCLUSIONS AND RELEVANCE: Among patients with early Parkinson disease, nicotinamide riboside treatment for 52 weeks did not improve clinical outcomes and was associated with worse clinical outcomes than placebo. These findings do not support nicotinamide riboside as a disease-modifying treatment for Parkinson disease. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03568968.
引用
- Brakedal B, Skeie GO, Derad C, et al. Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial. JAMA. 2026. PMID: 42848371. doi:10.1001/jama.2026.18828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。